2/26
02:56 pm
cytk
Cytokinetics (CYTK) had its price target raised by Leerink Partners from $83.00 to $84.00. They now have an "outperform" rating on the stock.
Low
Report
Cytokinetics (CYTK) had its price target raised by Leerink Partners from $83.00 to $84.00. They now have an "outperform" rating on the stock.
2/25
07:05 pm
cytk
Cytokinetics (CYTK) had its "neutral" rating reaffirmed by Bank of America Corporation.
Low
Report
Cytokinetics (CYTK) had its "neutral" rating reaffirmed by Bank of America Corporation.
2/25
08:03 am
cytk
Cytokinetics (CYTK) had its price target raised by Needham & Company LLC from $84.00 to $85.00. They now have a "buy" rating on the stock.
Medium
Report
Cytokinetics (CYTK) had its price target raised by Needham & Company LLC from $84.00 to $85.00. They now have a "buy" rating on the stock.
2/25
08:03 am
cytk
Cytokinetics (CYTK) had its price target raised by Citizens Jmp from $88.00 to $96.00. They now have a "market outperform" rating on the stock.
Medium
Report
Cytokinetics (CYTK) had its price target raised by Citizens Jmp from $88.00 to $96.00. They now have a "market outperform" rating on the stock.
2/24
11:25 pm
cytk
Cytokinetics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Cytokinetics Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
06:47 pm
cytk
Cytokinetics (CYTK) Q4 2025 Earnings Transcript [Yahoo! Finance]
Medium
Report
Cytokinetics (CYTK) Q4 2025 Earnings Transcript [Yahoo! Finance]
2/24
04:23 pm
cytk
Cytokinetics: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Cytokinetics: Q4 Earnings Snapshot [Yahoo! Finance]
2/24
04:00 pm
cytk
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
High
Report
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
2/20
09:36 am
cytk
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Royal Bank Of Canada from $95.00 to $101.00. They now have an "outperform" rating on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Royal Bank Of Canada from $95.00 to $101.00. They now have an "outperform" rating on the stock.
2/19
02:47 pm
cytk
Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space [Yahoo! Finance]
Low
Report
Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space [Yahoo! Finance]
2/17
07:30 am
cytk
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Low
Report
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
2/13
12:33 am
cytk
Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness [Yahoo! Finance]
Medium
Report
Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness [Yahoo! Finance]
2/12
04:00 pm
cytk
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
Low
Report
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
2/9
07:30 am
cytk
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
Medium
Report
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
2/3
09:06 pm
cytk
Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
Low
Report
Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
2/3
08:12 am
cytk
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
1/28
08:06 am
cytk
Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]
Low
Report
Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]
1/28
08:03 am
cytk
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
1/27
01:39 pm
cytk
How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]
Low
Report
How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]
1/27
10:07 am
cytk
Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]
Low
Report
Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]
1/27
08:00 am
cytk
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
Low
Report
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
1/27
07:30 am
cytk
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Low
Report
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
1/23
02:24 pm
cytk
The Future of Cardiovascular Care [Forbes]
Low
Report
The Future of Cardiovascular Care [Forbes]
1/22
02:39 pm
cytk
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
Low
Report
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
1/21
10:17 am
cytk
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $95.00 price target on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $95.00 price target on the stock.